Abbott Laboratories (ABT): Rep. Gilbert Ray Cisneros Jr. (CA31) disclosed a partial sale $1K–$15K

$1,001–$15,000

Reported range · official band, not an exact amount

24 days

Disclosure lag

Traded

Dec 19, 2025

Disclosed

Jan 12, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 23, 2024CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
2. Oct 29, 2025FDAFDA device clearance: Seguin Annuloplasty Ring
3. Nov 5, 2025CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
4. Nov 13, 2025FDARecall: Alinity ci-series System Control Module (SCM), REF: 03R70-01, 03R70-20
5. Nov 13, 2025CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
6. Nov 18, 2025Company filing · Form 8-K · Temporary Suspension of Trading Under Registrant's Employee Benefit PlansSuspended trading under its employee plans
7. Nov 18, 2025CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
8. Nov 19, 2025Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors (and 1 more item)
9. Nov 24, 2025FDARecall: FreeStyle Libre 3 Sensor REF 72081-01 UDI-DI code: 00357599818005 The FreeStyle Libre 3 sensor is a component of the FreeStyle Libre 3 Continuous Glucose Monit…
10. Nov 24, 2025FDARecall: FreeStyle Libre 3 Plus Sensor REF 78768-01 UDI-DI code: 00357599844011 The FreeStyle Libre 3 Plus sensor is a component of the FreeStyle Libre 3 Continuous Glu…
11. Nov 24, 2025FDARecall: FreeStyle Libre 3 Plus Sensor REF 78769-01 UDI-DI code: 00357599843014 The FreeStyle Libre 3 Plus sensor is a component of the FreeStyle Libre 3 Continuous Glu…
12. Nov 24, 2025FDARecall: FreeStyle Libre 3 Plus Sensor REF 72080-01 UDI-DI code: 00357599819002 The FreeStyle Libre 3 Plus sensor is a component of the FreeStyle Libre 3 Continuous Glu…
13. Nov 25, 2025InsiderOfficer sold ~$203K of ABT shares in the open market
14. Dec 3, 20255% stakeThe Vanguard Group reported a passive stake (13G) of 10.1%
15. Dec 4, 2025Congress · 1 personMembers of Congress: 2 sales
16. Dec 8, 2025CongressDisclosed sale of ABT — reported range $1,001 - $15,000
17. Dec 12, 2025Company filing · Form 8-K · Executive change, Bylaws or charterChanged a top executive or board member, and changed its bylaws, charter or fiscal year“On December 12, 2025, Nita Ahuja, M.D. was named to the Abbott Laboratories’ (“Abbott”) Board of Directors.”
18. Dec 17, 2025FDAFDA device clearance: Amplatzer Piccolo™ Delivery System (9-PDS-04F-045)
19. Dec 18, 2025FDAFDA device clearance: Assert-IQ (DM5100)
20. Dec 18, 2025CongressDisclosed sale of ABT — reported range $1,001 - $15,000
21. Dec 19, 2025 · this disclosureCongressDisclosed partial sale of ABT — reported range $1,001 - $15,000

What came next

1. Dec 19, 2025FDAFDA device approval: Volt™ PFA System
2. Jan 22, 2026Company filing · Form 8-K · ResultsReported its results
3. Jan 23, 2026Insider · First insider buy since Feb 2021CEO purchased ~$2.01M of ABT shares in the open market
4. Jan 29, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
5. Feb 4, 2026Insider · 1 personInsiders: 2 purchases (~$1.1M)
6. Feb 10, 2026CongressDisclosed partial sale of ABT — reported range $1,001 - $15,000
7. Feb 13, 2026FDAFDA device clearance: Armada™ 14 NC PTA Catheter
8. Feb 20, 2026Company filing · Form 8-K · Bylaws or charterChanged its bylaws, charter or fiscal year
9. Feb 23, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
10. Mar 2, 2026Insider · 6 peopleInsiders: 6 sales (~$485K)
11. Mar 9, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
12. Mar 13, 2026FDAFDA device clearance: Amplatzer™ Trevisio™ Intravascular Delivery System; 9-ATV06F45/609-ATV07F45/609-ATV07F45/809-ATV08F45/609-ATV08F45/809-ATV09F45/809-ATV10F45/809-ATV12F45/80
13. Mar 19, 2026CongressDisclosed purchase of ABT — reported range $1,001 - $15,000
14. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
15. Apr 16, 2026Company filing · Form 8-K · ResultsReported its results
16. Apr 16, 2026FDAFDA device clearance: Disposable Radiofrequency Cannula

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Abbott Laboratories

For Abbott Laboratories, OQRO holds 5 insider filings (SEC Form 4 or Form 144), 6 Congress trade reports and 59 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABT page.

Other recent filings by Rep. Gilbert Ray Cisneros Jr. (CA31)

• House Clerk periodic transaction report at Atricure (ATRC)Oct 12, 2026
• House Clerk periodic transaction report at Balchem Corporation (BCPC)Oct 12, 2026
• House Clerk periodic transaction report at Benchmark Electronics, Inc. (BHE)Oct 12, 2026
• House Clerk periodic transaction report at Bridgebio Pharma (BBIO)Oct 12, 2026
• House Clerk periodic transaction report at Broadcom (AVGO)Oct 12, 2026

The full history of Rep. Gilbert Ray Cisneros Jr. (CA31) is on the profile page.

How this filing works

• The STOCK Act

Other disclosures at Abbott Laboratories

• House Clerk periodic transaction reportOct 30, 2026
• House Clerk periodic transaction reportOct 27, 2026
• House Clerk periodic transaction reportOct 12, 2026
• SEC Form 4Sep 3, 2026
• SEC Form 144Sep 2, 2026
• SEC Form 4Aug 27, 2026

Everything OQRO holds on this company is on its ABT page.